Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $6.18

Key Points

• Health Catalyst, Inc. (NASDAQ:HCAT) has received an average rating of "Hold" from twelve brokerage firms, with seven hold recommendations and five buy ratings.
• The average 12-month price target for Health Catalyst shares is $6.18, with notable declines in target prices from firms such as Stifel Nicolaus and Citigroup.
• Approximately 85% of Health Catalyst stock is owned by hedge funds and institutional investors, indicating strong institutional interest in the company.

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have earned a consensus rating of "Hold" from the twelve ratings firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $5.4167.

Several equities analysts have recently commented on HCAT shares. BTIG Research downgraded Health Catalyst from a "buy" rating to a "neutral" rating in a research report on Tuesday, June 17th. Citigroup cut Health Catalyst from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $6.50 to $3.50 in a report on Friday, August 8th. Wells Fargo & Company reduced their target price on Health Catalyst from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. Canaccord Genuity Group reduced their target price on Health Catalyst from $9.00 to $5.00 and set a "buy" rating on the stock in a report on Friday. Finally, Stifel Nicolaus reduced their target price on Health Catalyst from $5.50 to $4.50 and set a "hold" rating on the stock in a report on Friday, August 8th.

Institutional Investors Weigh In On Health Catalyst

Several large investors have recently made changes to their positions in HCAT. Group One Trading LLC increased its stake in Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock worth $31,000 after acquiring an additional 2,260 shares during the last quarter. Cresset Asset Management LLC bought a new stake in Health Catalyst during the second quarter worth approximately $39,000. Divergent Planning LLC bought a new stake in Health Catalyst during the second quarter worth approximately $45,000. Focus Partners Wealth bought a new stake in Health Catalyst during the first quarter worth approximately $46,000. Finally, XTX Topco Ltd bought a new stake in Health Catalyst during the first quarter worth approximately $54,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded down $0.26 during trading hours on Wednesday, hitting $3.39. The company's stock had a trading volume of 985,703 shares, compared to its average volume of 1,109,481. The business has a 50 day moving average price of $3.62 and a two-hundred day moving average price of $3.97. Health Catalyst has a 12-month low of $2.52 and a 12-month high of $9.24. The company has a market cap of $238.55 million, a PE ratio of -2.25 and a beta of 1.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.